June 15, 2026

@michaelokun

The levodopa paradox: a medication, a biomarker, and a prognostic clue? Levodopa responsiveness refers to how much a person's parkinsonian symptoms improve when treated w/ levodopa; the most effective symptomatic therapy for Parkinson's disease. Arca and colleagues describe in a new paper in Annals of Neurology how levodopa responsiveness relates to diagnosis, prognosis, and underlying pathology across Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Key points: - In pathology-confirmed Parkinson's disease, 86% of patients demonstrated a definite and sustained levodopa response, while 14% did not despite having PD pathology. - A definite levodopa response in PD was associated w/ a 55% lower risk of falls, a 69% lower risk of dementia, and a 69% improvement in survival. - Definite levodopa responsiveness showed excellent diagnostic accuracy in distinguishing PD from MSA and PSP, whereas acute levodopa challenge testing was considerably less informative. My take: This paper tackles one of the oldest questions in movement disorders: how much should we trust the levodopa response? The answer appears to be quite a lot, especially when the response is robust and sustained over years. What struck me most was that levodopa responsiveness was not simply a treatment effect. It carried important prognostic information. Folks w/ PD who enjoyed a durable response experienced fewer falls, less dementia, and lived longer. Equally interesting was that a small number of patients w/ MSA and PSP also responded, reminding us that biology is more nuanced than clinical stereotypes. The study reinforces why longitudinal observation still matters, even in an era of biomarkers and AI. Levodopa response definitely matters when choosing DBS candidates.